Conformational Radiotherapy of Prostatic Adenocarcinoma at the Dalal Jamm Hospital, Senegal—(Retrospective Analysis of a Series of 62 Cases)  

作　　者：Mouhamadou Bachir Ba Amadou Ibra Diallo Fatimatou Néné Sarr El Hadji Aliou Baldé Ibrahima Thiam Papa Macoumba Gaye Mouhamadou Bachir Ba;Amadou Ibra Diallo;Fatimatou Néné Sarr;El Hadji Aliou Baldé;Ibrahima Thiam;Papa Macoumba Gaye(Radiotherapy Department, Dalal Jamm Hospital, UCAD, Dakar, Senegal;Preventive Medicine and Public Health Service, Health and Development Institute, UCAD, Dakar, Senegal)

机构地区：[1]Radiotherapy Department, Dalal Jamm Hospital, UCAD, Dakar, Senegal [2]Preventive Medicine and Public Health Service, Health and Development Institute, UCAD, Dakar, Senegal

出　　处：《Journal of Cancer Therapy》2020年第10期631-638,共8页癌症治疗（英文）

摘　　要：<strong>Aim:</strong><span><span><span style="font-family:""><span style="font-family:Verdana;"> We endeavored to describe the epidemiological profile of prostatic cancer, and to evaluate its diagnostic and therapeutic aspects. </span><b><span style="font-family:Verdana;">Method:</span></b><span style="font-family:Verdana;"> We conducted a descriptive retrospective study on the conformational radiotherapy of prostatic adenocarcinoma at the Dalal Jamm University Hospital, Senegal from June 2018 to December 2019. We included 62 consecutive patients. The average age of the patients was 68.9 years. The average consultation time was 7.6 months. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> Symptom manifestation and high PSA triggered the diagnosis of cancer in 74.2% and 25.8% of patients, respectively. Symptoms: pollakiuria (72.3%), bone pain (8%) and erectile dysfunction (4.8%). The digital rectal examination: normal (33.8%), nodular (30.6%), induration (24.1%), and shielding (11.3%). The mean PSA level was 90.6 ng/ml. Histology: adenocarcinoma was the most common (98.6%). The Gleason score: <7 (45.1%), =7 (35.5%), and >7 (19.4%). The majority of patients were in the high-risk group (70.9%) and 7 patients (11.2%) were metastatic at diagnosis. Therapy: first radical prostatectomy (20.9%), first-line curative radiotherapy (67.8%), adjuvant (21%) and palliative radiotherapy in 7 patients (11.2%): patients having received palliative radiotherapy had an estimated decline in symptoms of 80%. Hormone therapy was performed in 88.8% of patients, with average duration of 12.5 months. After a mean follow-up of 15 months, 59 patients were alive, including 45 cases (81.8%) in complete remission;3 patients with metastasis at the first visit (having received palliative ra</span><span><span style="font-family:Verdana;">diotherapy) died. </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> The collected data show a profile of prost<strong>Aim:</strong><span><span><span style="font-family:""><span style="font-family:Verdana;"> We endeavored to describe the epidemiological profile of prostatic cancer, and to evaluate its diagnostic and therapeutic aspects. </span><b><span style="font-family:Verdana;">Method:</span></b><span style="font-family:Verdana;"> We conducted a descriptive retrospective study on the conformational radiotherapy of prostatic adenocarcinoma at the Dalal Jamm University Hospital, Senegal from June 2018 to December 2019. We included 62 consecutive patients. The average age of the patients was 68.9 years. The average consultation time was 7.6 months. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> Symptom manifestation and high PSA triggered the diagnosis of cancer in 74.2% and 25.8% of patients, respectively. Symptoms: pollakiuria (72.3%), bone pain (8%) and erectile dysfunction (4.8%). The digital rectal examination: normal (33.8%), nodular (30.6%), induration (24.1%), and shielding (11.3%). The mean PSA level was 90.6 ng/ml. Histology: adenocarcinoma was the most common (98.6%). The Gleason score: <7 (45.1%), =7 (35.5%), and >7 (19.4%). The majority of patients were in the high-risk group (70.9%) and 7 patients (11.2%) were metastatic at diagnosis. Therapy: first radical prostatectomy (20.9%), first-line curative radiotherapy (67.8%), adjuvant (21%) and palliative radiotherapy in 7 patients (11.2%): patients having received palliative radiotherapy had an estimated decline in symptoms of 80%. Hormone therapy was performed in 88.8% of patients, with average duration of 12.5 months. After a mean follow-up of 15 months, 59 patients were alive, including 45 cases (81.8%) in complete remission;3 patients with metastasis at the first visit (having received palliative ra</span><span><span style="font-family:Verdana;">diotherapy) died. </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> The collected data show a profile of prost

关 键 词：CANCER PROSTATE RADIOTHERAPY Senegal 

分 类 号：R73[医药卫生—肿瘤]